āļāļēāļĢāļ§āļīāļāļąāļĒāđāļāļīāļāļĨāļķāļāđāļĨāļ°āļāļđāđāļĄāļ·āļāļāļđāđāđāļāļĩāđāļĒāļ§āļāļēāļāđāļāļĩāđāļĒāļ§āļāļąāļāļāļēāļĢāļĢāļąāļāļĐāļēāļŠāļļāļāļ āļēāļāļŠāļēāļĒāļāļēāļāļāļāļāļļāļ
Introduction Glaucoma affects tens of millions worldwide and is the second leading cause of irreversible blindness after cataract (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Most cases progress silently, and roughly 3% of adults over 40 have glaucoma â the majority undiagnosed (pmc.ncbi.nlm.nih.gov). Visual loss from glaucoma heavily degrades quality of life and raises lifetime costs; one s...
āđāļĢāļīāđāļĄāļāļēāļĢāļāļāļŠāļāļāļĨāļēāļāļŠāļēāļĒāļāļēāļāļĢāļĩāļāļāļāļāļļāļāđāļāđāļ§āļĨāļēāļāđāļāļĒāļāļ§āđāļē 5 āļāļēāļāļĩ
āđāļĢāļīāđāļĄāļāļāļŠāļāļāļāļąāļāļāļĩTesting people who have no symptoms to find eye disease early, such as vision checks or pressure tests. Screening matters because catching problems sooner usually makes treatment more effective.
ðĨāļāļāļāļ§āļēāļĄāļĒāļāļ
